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Bacterial survivalLysozymes play an important role in host defense by degrading peptidoglycan in the cell envelopes of pathogenic
bacteria. Several Gram-negative bacteria can evade this mechanism by producing periplasmic proteins that
inhibit the enzymatic activity of lysozyme. The Escherichia coli inhibitor of vertebrate lysozyme, Ivyc and its
Pseudomonas aeruginosa homolog, Ivyp1 have been shown to be potent inhibitors of hen egg white lysozyme
(HEWL). Since human lysozyme (HL) plays an important role in the innate immune response, we have examined
the binding of HL to Ivyc and Ivyp1. Our results show that Ivyp1 is a weaker inhibitor of HL than Ivyc even though
they inhibit HEWLwith similar potency. Calorimetry experiments conﬁrm that Ivyp1 interactsmoreweaklywith
HL than HEWL. Analytical ultracentrifugation studies revealed that Ivyp1 in solution is a monomer and forms a
30 kDa heterodimer with both HL and HEWL, while Ivyc is a homodimer that forms a tetramer with both
enzymes. The interaction of Ivyp1 with HL was further characterized by NMR chemical shift perturbation
experiments. In addition to the characteristic His-containing Ivy inhibitory loop that binds into the active
site of lysozyme, an extended loop (P2) between the ﬁnal two beta-strands also participates in forming
protein–protein interactions. The P2 loop is not conserved in Ivyc and it constitutes a ﬂexible region in Ivyp1
that becomes more rigid in the complex with HL. We conclude that differences in the electrostatic interactions
at the binding interface between Ivy inhibitors and distinct lysozymes determine the strength of this interaction.
This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
During bacterial infections, lysozymes and proteinaceous lysozyme
inhibitors are part of the molecular warfare that is deployed between
vertebrate hosts and bacteria. Lysozymes are host defense enzymes
that act as a protective barrier against colonization and invasion by bac-
terial pathogens. They exert their activity by hydrolysing the β-1,4 gly-
cosidic bonds of peptidoglycan, a polysaccharide unique to the bacterial
cell wall [1]. The antibacterial activity is stronger against Gram-positive
than against Gram-negative bacteria where peptidoglycan accessibility
is hindered by the presence of the outer membrane. However, the
production of accessory antibacterial proteins which permeabilize theEWL, hen eggwhite lysozyme;
AUC, analytical ultracentrifuga-
ar magnetic resonance; HSQC,
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ial resistance to antimicrobial
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; fax: +1 403 289 9311.outermembrane, such as lactoferrin, renders also Gram-negative bacte-
ria a lysozyme target [2,3]. Three major lysozyme types have been
identiﬁed to date and are designated as c-type (chicken or conventional),
g-type (goose), and i-type (invertebrate) [4,5]. Although the overall
sequence similarity among c-, g-, and i-type lysozymes is limited,
their three dimensional structures share signiﬁcant similarities.
The best studied member of c-type lysozymes, the major type of
vertebrates, is HEWL (hen egg white lysozyme), the ﬁrst enzyme to
have its structure determined by X-ray crystallography [6]. The enzyme
is approximately ellipsoidal in shape, with two structural lobes divided
by a large cleft that contains the active site [6–8].
Because of the effectiveness of lysozyme as an antibacterial agent, it
is perhaps not surprising that somepathogenic and commensal bacteria
have evolved defense strategies to escape from the threat posed by lyso-
zyme. Examples of such mechanisms are the chemical modiﬁcation of
peptidoglycan in the bacterial cell wall [9–11] and the synthesis of a
protein named SIC (streptococcal inhibitor of complement) which was
shown to bind lysozyme, albeitweakly [12]. More recently two different
families of speciﬁc inhibitors of c-type lysozymes have been discovered
[13,14]. The ﬁrst identiﬁed member of the Ivy (inhibitor of vertebrate
lysozyme) family is the product of the Escherichia coli ORF gene ykfE
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least 35 members of Proteobacteria (Gram-negative bacteria) within
the periplasmic compartment, but unexpectedly not in Gram-positive
ones [15]. PliC, a periplasmic lysozyme inhibitor of c-type lysozymes
originally isolated from Salmonella enteriditis and MliC, a membrane-
bound lysozyme inhibitor of c-type lysozymes anchored to the luminal
face of the outer membranes of E. coli and P. aeruginosa, represent a sec-
ond, larger family of c-type lysozyme inhibitors which is predicted to
have homologs in at least 52 different genera of Protobacteria and
occur in Acidobacteria, Cyanobacteria, and Bacteroides groups [14].
Recently, other protein inhibitors of lysozyme were described for
Moraxella catarrhalis, suggesting that this bacterial evasion mechanism
may be more widespread [16].
Themechanism of inhibition by PliC andMliC has recently been elu-
cidated by analyzing the structures of their complexes with lysozyme
[17–21]. The structures of Ivyc and of its evolutionary distant homolog
from P. aeruginosa, Ivyp1, and their complexes with HEWL have also
been determined by X-ray crystallography [15] shedding some light
on their mechanism of inhibition. Ivyc is a dimer in the crystal structure.
Each monomer of the Ivyc dimer consists of a central β-sheet made up
of ﬁve antiparallel β-strands ﬂanked by two shortα-helices on the con-
vex side and by an amphipatic helix on the concave side. In solution,
Ivyc likewise appears to be predominantly dimeric as estimated from
gel ﬁltration experiments [13]. The structure reveals that the dimer in-
volves interactions among residues that are located in the C-terminal
part of the molecule and are conserved in various E. coli strains as well
as in homologous amino acid sequences from Shigella ﬂexneri, Klebsiella
pneumoniae, and Burkholderia cepacia. However, in other bacteria Ivy
seems to be monomeric, and P. aeruginosa Ivyp1, which lacks many of
the conserved C-terminal residues involved in dimer formation, is a
monomeric protein with a similar structure to the Ivyc monomer [15].
The crystallographic structures of the Ivyc–HEWL and Ivyp1–HEWL
complexes show that the Ivyp1 monomer interacts with one HEWL
molecule while the Ivyc–HEWL crystal unit contains one Ivyc homodi-
mer in complex with two HEWL molecules [15]. Interestingly, in the
Ivyc–HEWL complex each HEWL molecule interacts with both Ivyc
molecules through two interacting surfaces. The deduced mechanism
of lysozyme inhibition by the Ivy molecules suggests that the lysozyme
active site becomes occluded by a loop protruding from the Ivy
molecules. The sequence of the inhibitory loop (CKPHDC) is strictly
conserved among a subset of Ivy homologs even in distantly related
bacteria. A disulﬁde bond linking the two cysteine residues on both
sides of this sequence provides some rigidity to this loop.
The inhibitory loop sequence is not conserved in several Ivy paralogs
found in the Pseudomonas species and is replaced with a more variable
sequence ﬂanked by two conserved cysteine residues (CExxDxC). One
of these inhibitors, Ivyp2 has been shown to lack the ability to inhibit ly-
sozyme despite their overall sequence similarity. Recently, a new role
has been proposed for these paralog sequences [22], namely, the inhibi-
tion of lytic transglycosylases (LTG), a group of enzymes responsible for
endogenous peptidoglycan lysis. LTGs share the same speciﬁcity of
cleavage as the lysozymes. Interestingly, Ivyp1 also inhibits LTGs and
it was therefore suggested that the inhibition of LTGs may be the true
physiological function of the Ivy proteins. However, several recent
in vivo studies have conﬁrmed that the Ivy proteins can play a major
role in the evasion mechanisms of pathogenic bacteria by inhibiting ly-
sozyme. For example, recent work with Edwardsiella tarda [23], Yersinia
pestis [24], and avian pathogenic E. coli [25] showed that Ivy deletion
mutants had reduced virulence in a species dependent manner. More-
over, overexpression of Ivy proteins in various E. coli organisms gave
rise to increased bacterial growth in lysozyme containing media [26].
These studies all reinforce the original work of Deckers et al, who dem-
onstrated by making knockouts and overproducing strains that Ivyc
protected E. coli against lysozyme [27]. Taken together, it seems clear
that the bacterial Ivy proteins are multifunctional and that they can
play a role in evading the lysozyme-mediated host response [28].Ivyc was shown to be a strong inhibitor of HEWL, but inhibited
λ-phage lysozyme and goose egg white lysozyme only weakly [13,29].
While Kd values of 1 nM and 25 nMwere reported for the inhibition of
HEWL by Ivyc and Ivyp1, respectively, no quantitative inhibition data is
available for HL (human lysozyme) or any other c-type lysozymes. The
structure of HL [30] reveals important differenceswith respect to HEWL
in the residues located at the interface of the HEWL–Ivy complexes,
which are expected to affect the strength of interaction and
consequently the Ivy inhibitory effect. Moreover because HL has a
higher speciﬁc activity, and since it plays important roles in the
human host-defense in various bioﬂuids, such as milk, saliva, tears, air-
way epithelium, and blood [31–35], it is important to study the interac-
tion of Ivyc and Ivyp1withHL in comparisonwithHEWL. Consequently,
in this work, in addition to enzymatic inhibition experiments, wemon-
itored the interaction of these proteins by isothermal titration calorim-
etry (ITC), analytical ultracentrifugation (AUC), differential scanning
calorimetry (DSC), and NMR spectroscopy. Our results show that Ivy
proteins differ in their interaction with different c-type lysozymes.
2. Material and methods
2.1. Chemicals and reagents
Unless stated otherwise all reagents were purchased from Sigma-
Aldrich (St. Louis,Missouri). Recombinant HLwas produced from a syn-
thetic codon-optimised gene in Pichia pastoris in our lab (unpublished
data) or purchased from Sigma-Aldrich as a recombinant enzyme pro-
duced in rice (L-1667). Both enzymes proved to be N95% pure and
displayed approximately the same speciﬁc activity (data not shown)
using the turbidimetric assay described below.
2.2. Cloning of Ivyc and Ivyp1
The 387 bp DNA fragment encoding the mature form of Ivyc and
Ivyp1 without its signal peptide was PCR ampliﬁed from E. coli K12
and P. aeruginosa PA14, respectively using Pfu polymerase (Fermentas).
The primers used for the PCR ampliﬁcation were synthesized at the
University Core DNA Services, Calgary and the sequences are listed
below:
IvycF: 5′-GATATACATATGCAGGATGATTTAACCATTAGCAGC-3′
IvycR: 5′-GTGGTGCTCGAGTTTAAAATTAAAGCCATCCGGATGG-3′
IvypF: 5′-GTTAATCATATGGAGCAGCCGCGGC-3′
IvypR: 5′-CAATAACTCGAGCTTCCAGTTCGGATC-3′.
Restriction sites for NdeI and XhoI were added at each end of the
primers and are underlined to allow ligation into the expression vector.
The PCRproductswereﬁrst puriﬁed using theQIAquick PCR Puriﬁcation
Kit (Qiagen) and then digestedwith NdeI and XhoI restriction enzymes.
The puriﬁed digested products were ligated into pET29b (EMD Biosci-
ences) using T4 DNA ligase.
2.3. Expression and puriﬁcation of Ivyc and Ivyp1
E. coli BL21(DE3) cells transformedwith the puriﬁed expression plas-
mids carrying the correct sequence for mature Ivyc and Ivyp1 were
grown in LB medium supplemented with 30 μg/mL kanamycin at 37 °C
until exponential phase (OD600 nm approximately 0.7). Overexpression
was induced with 1 mM isopropyl-1-thio-β-D-galactopyranoside
(IPTG) and the culture was grown for another 3–4 h at 37 °C before
the cells were harvested by centrifugation at 6000 rpm for 15 min at
4 °C. The cell pellet was resuspended in Buffer A (20 mM Tris-HCl
pH 8.0, 500 mM NaCl, 75 mM imidazole) containing 0.8 mg/mL
phenylmethylsufonyl ﬂuoride (PMSF) and lysed by using three pas-
sages through a French Pressure Cell Press. The lysate was centrifuged
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Ni-Sepharose 6 Fast Flow column (GE Healthcare). Contaminanting
proteins were removed by washing with ten-column volumes of Buffer
A prior to elution of the His-tagged inhibitors with ﬁve column volumes
of Buffer B (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 250 mM imidazole).
Fractions containing Ivyc or Ivyp1were pooled and dialyzed extensively
against 10 mM ammonium bicarbonate (pH 7.78) at 4 °C before
lyophilization.
For the NMR experiments, the Ivyp1 DNA fragment was ampliﬁed
from the pET29b template and inserted into a pSUMO vector with re-
striction sites KpnI and BamHI. A TEV protease cleavage sequence was
introduced between the SUMO and the Ivyp1 sequence [36]. The ﬁnal
expression plasmid was transferred into E. coli BL21 (DE3) and protein
expression was examined in small scale LB medium (~5 mL) with
100μg/mL ampicillin at 37°. Large scale protein expression and puriﬁca-
tion are similar as those expressed with pET29b vector. After protein
was eluted with high imidazole buffer (Buffer B), fractions containing
SUMO-Ivyp1 were pooled together and dialyzed overnight against
Buffer C (20 mM Tris-HCl pH 8.0, 150 mM NaCl). Dialyzed SUMO-
Ivyp1 was digested at 34 °C with TEV protease in Buffer D (Buffer C
with 0.5 mM EDTA and 1 mM 2-mercaptoethanol). Digested protein
was dialyzed again in Buffer C overnight to remove EDTA and 2-
mercaptoethanol. After the second dialysis, the SUMO fusion tag and
TEV protease were removed by reloading the digest on the Ni-
Sepharose 6 column. Flow-through fractions containing Ivyp1were col-
lected and dialyzed against 10 mM ammonium bicarbonate at 4 °C be-
fore lyophilization. Isotope-labeled wild-type and mutant (H20A)
proteins were expressed in M9 media supplemented with 15NH4Cl
(1 g/L) and/or 13C-glucose. Protein puriﬁcation procedures were the
same as for the non-labeled proteins.
2.4. NMR experiments
All NMR spectra were acquired on either a Bruker AVANCE 700MHz
NMR spectrometer equippedwith a triple resonance inverse cryo-probe
with a single axis z gradient or a Bruker AVANCE 600MHz with a triple
resonancewith a single axis z gradient (TXI) probe. Two 13C/15N-labeled
NMR samples were prepared for the backbone resonance assignments
of unbound and lysozyme-bound Ivyp1. Both samples contained
500 μMIvyp1 in 50mMsodiumphosphate buffer (pH6.4). The complex
sample was made by titrating unlabeled HL into Ivyp1 sample. No fur-
ther chemical shift changes in the 1H,15NHSQC spectrumwere observed
after excess lysozyme (1.5molar equivalent) was added. All NMR back-
bone resonance assignment experiments (CBCACONH, HNCACB, HNCO
and HN(CA)CO) [37,38] were acquired at 310 K. An internal standard
(2,2-dimethyl-2-silapentane-5-sulfonate, DSS) was used as the proton
chemical shift reference. All data were processed with NMRPipe [39]
and the spectra were analyzed by NMRView [40].
The secondary structures of Ivyp1 alone and in complex with HL
were estimated by the weighted average secondary shifts (WASS),
which were calculated by the averaged differences between the
chemical shifts of protein backbone Cα, C′ and N nuclei and those from
the random coil (Eq. (1)).
WASS ¼ δCα‐δCαrð Þ þ 1:7 δC0‐δC0rð Þ þ 0:35 δN‐δNrð Þ½ =3: ð1Þ
Chemical shift differences between the unbound and bound Ivyp1
were calculated by recording chemical shift perturbations (CSP) [41]
and a simpliﬁed equation is used here (Eq. (2)):
CSP ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ΔHNð Þ2 þ ΔN=5ð Þ2
q
: ð2Þ
{1H},15N NOE experiments were acquired for Ivyp1 in the presence
and absence of HL on the 600 MHz spectrometer at 310 K. The NOE
and reference spectra were recorded alternatively with and without a1H saturation pulse. The recycle delay is 5 s [42]. The NOE data were
processed by NMRPipe and NOE values were calculated with the NOE
analysis module in NMRView.
To monitor the protonation state of the histidine sidechain, we used
the 1H,13C constant-time HSQC experiment [43] to record the reso-
nances of 1Hε1 and 13Cε1 on the 700MHzNMR spectrometer at different
pH values ranging from 4–10 at 310 K. The spectral widths are 9765.6
(2048 total points) and 1760.7 Hz (64 points) for the 1H and 13C dimen-
sion, respectively. The carrier frequencies were 4.7 ppm and 137 ppm
for the 1H and 13C channels. All HSQC spectra were processed with
NMRPipe and the chemical shifts of 1Hε1 and 13Cε1 resonances of
the His20 and His62 residues were recorded at each pH. These pH-
dependent chemical shifts were ﬁtted to a modiﬁed Henderson–
Hasselbalch equationwith a nonlinear least-square analysis (SigmaPlot,
SPSS Inc.):
δobs ¼ δXHþƒXHþ þ δXƒX: ð3Þ
The percentage of the fully protonated ( ƒXH+, δXH+) and
deprotonated (ƒX, δX) states were calculated by the following equations:
f XHþ ¼
10pKa−pH
1þ 10pKa−pH ð4Þ
f X ¼ 1− f XHþ : ð5Þ
2.5. Inhibition assays
A turbidimetric assay [44] was used to monitor the inhibition of the
HEWL and HL activity by the Ivy proteins. Using a Genesys 10 UV-Vis
Scanning Spectrophotometer we ﬁrst measured the decrease in turbid-
ity at OD570 nm of aMicrococcus lysodeikticus (Sigma) suspension caused
by the lysis of the cell wall peptidoglycan by HEWL or HL over time.
The assay was performed at room temperature and in 0.1 M Na3PO4,
pH 6.4 buffer. For the inhibition assays, Ivyc and Ivyp1 at different
concentrations were pre-incubated with a 70 nM solution of HEWL
or HL for 15 min prior to the addition of theM. lysodeikticus suspen-
sion (0.35 mg/mL).
The reaction velocities in the absence (vo) and in the presence of
inhibitors (vi) were calculated as the slope of each assay curve. The
equilibrium dissociation constants (Kiapp) were determined by a non-
linear regression ﬁtting of the vi/vo vs inhibitor concentration plots to
the Morrison equation for tight binding inhibitors [45].
2.6. Isothermal titration calorimetry
The interaction between HEWL and HL with Ivyc and Ivyp1 was
assessed by ITC using a MicroCal VP-ITC microcalorimeter. The lyophi-
lized inhibitors were resuspended in ITC buffer (50 mM Tris-HCl buffer
pH 7.0, 150mMNaCl) at approximately 200 μM and were placed in the
syringe of the ITC. HEWL and HL (Sigma) were resuspended in ITC
buffer and passed through a PD10 (Bio-Rad) size-exclusion columnpre-
viously equilibrated in ITC buffer in order to remove any small molecu-
lar contaminants present in the commercially puriﬁed enzymes. ITC
titrations were performed at room temperature and consisted of 30
injections of 10 μL solution of each inhibitor (200 μM) into a 1.43 mL
sample cell containing solutions of HEWL or HL (20 μM). The titration
curves were ﬁtted to a one-site binding model using the MicroCal
Origin software. The stoichiometry (N), association constant (Ka), and
enthalpy change (ΔH) were obtained directly from the ITC data while
dissociation constants (Kd) were calculated as 1/Ka. Average Kd values
were determined from at least 3 replicates.
Fig. 1. Inhibition of HL by Ivyc (A) and Ivyp1 (B). Inhibition of HEWL by Ivyc and Ivyp1 is displayed for comparison as insets in Panels A and B. Ivyc (0–140 nM) and Ivyp1 (0–10 μM)were
pre-incubatedwith a 70 nM solution of HEWL or HL for 15 min prior to the addition of theM. lysodeikticus suspension (0.35mg/mL). The reaction velocities in the absence (vo) and in the
presence of inhibitors (vi) were calculated as the slope of each assay curve. Apparent Ki values were determined by a non-linear regression ﬁtting of the vi/vo vs inhibitor concentration
plots to the Morrison equation for tight binding inhibitors [45].
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All DSC experiments were performed on a VP-DSC
micorcalorimeter (MicroCal, Northampton, MA). Both lysozymesTable 1
Sedimentation behavior of Ivyc, Ivy p1, HEWL, and HL.
S20,w (S)
No DTT 2 mM DTT
Ivyp1 1.90 (80%)
4.50 (10%)
7.20 (10%)
1.80
Ivyc 2.80 (75%)
4.60 (10%)
6.0 (15%)
2.35
HL 1.80 n.d.
HEWL 1.80 n.d.and Ivys were dialyzed overnight in a 50 mM sodium phosphate
buffer (pH 7.4). Protein concentration was around 100–200 μM for
each protein. All complex samples were made by mixing two pro-
teins at a 1:1 ratio with a ﬁnal concentration of ~100 μM for each
component. Any precipitation was removed by centrifugation before
the samples were loaded. For each heating scan, a 10 min pre-scan
thermostat period and a 90 °C/h heat scanning speed (20–120 °C)
were used. The ﬁlter period was 16 s and a passive thermal compen-
sation between the reference and sample cells was chosen. Four
scans were used for each sample and the ﬁrst buffer scan was
discarded due to a scanning thermal “memory”. Each sample was
reﬁlled in a window between 40 °C and 20 °C during a passive
cooling period after the second buffer scan. After the sample scan,
the fourth scan was used to check the reversibility of the protein
thermal denaturation. The melting temperature (Tm) values were
determined with a built-in peak picking function and the curve-
ﬁtting algorithms in Origin 7.0. Except for Tm, both the calorimetric
S 
c(S
)
S 
c(S
)
A B
Fig. 2. Sedimentation pattern of Ivyc (A) and Ivyp1 (B) in the presence (solid line) and absence (dashed line) of DTT. In the absence of DTT, the S20,w values of the Ivyc components and
their respective amounts are 2.80 S (75%), 4.60 S (10%), and 6.0 S (15%). The corresponding values for the Ivyp1 components are: 1.90 S (80%), 4.50 S (10%), and 7.20 S (10%). In the
presence of reducing agent Ivyc and Ivyp1 display only one peak at 2.35 S and 1.80 S, respectively.
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py (ΔHv) resulting from the micorcal curve-ﬁtting were collected.
2.8. Analytical ultracentrifugation
Sedimentation velocity and equilibrium experiments were carried
out at 20 °C in 50 mM Tris-HCl containing 150 mM NaCl, pH 7.0 on a
Beckman-Coulter XL-I analytical ultracentrifuge, equipped with absor-
bance optics and an An60-Ti rotor. The lysozyme samples were
prepared at concentrations ranging from 0.2 to 2 mg/ml (13 μM to
130 μM). Sedimentation velocity experiments were performed at
50,000 rpm. Data were collected at 275 nm at a spacing of 0.003 cm
with three averages in a continuous scan mode. Sedimentation
coefﬁcients were obtained with the software SEDFIT (provided by
Dr. P. Schuck, National Institutes of Health). The values were reduced
to water (s20,w) using standard procedures. The buffer density and vis-
cositywere calculated by the software Sednterp. The ratio f/f0was calcu-
lated from the diffusion coefﬁcient, which is related to the spreading of
the boundary, using the program SEDFIT. The relative percentage of the
components was estimated from the area under the peaks.
Sedimentation equilibrium experiments were performed also at
20 °C at different concentrations in a range between 0.2 mg/ml
(13 μM) and 2.4 mg/ml (160 μM) at 10,000, 13,000 and 16,000 rpm in
50mMTris-HCl containing 150mMNaCl at pH 7.0. Data were collected
every 3 h at a spacing of 0.001 cmwith 10 averages in a step scanmode.
The attainment of equilibrium was assessed by comparing scans up to
24 h by the software WINMATCH. Data sets were edited by REEDITTable 2
Sedimentation behavior of Ivy-Lysozyme complexes at different molar ratios.
S20,w (S)
1:1 1:2
Ivyp1:HEWL 1.9 (80%)
2.9 (10%)
4.5 (10%)
1.9
2.9
Ivyc:HEWL 1.8 (75%)
4.3 (10%)
6.4 (15%)
1.8
Ivyp1:HL 2.8 2.5
Ivyc:HL 4.2 4.3 (70%)
1.9 (30%)(J. Lary, National Analytical Ultracentrifugation Center, Storrs, CT) and
analyzed by the software Sedphat, provided by the National Institutes
of Health. Molecular weights were determined by a global ﬁt of the
sedimentation data. The partial speciﬁc volume and density of the
samples were calculated using the program SEDNTERP from the
amino acid sequence and buffer composition, respectively.
3. Results
3.1. Inhibition of HL and HEWL by Ivyc and Ivyp1
An estimated Ki value of 1 nM for the inhibition of HEWL by Ivyc has
been reported [13,15] and inhibition of HL by this inhibitor has also
been shown using human saliva but no Ki value was measured in this
case.We decided to extend on these original studies by looking in detail
into the HL inhibition properties of Ivyc and its P. aeruginosa homolog,
Ivyp1.
Using the turbidimetric assay described in the methods section we
determined the effect of different amounts of Ivyc and Ivyp1 on the
enzymatic activity of HL and HEWL. In the case of Ivyc the range of
concentrations used was 0–140 nM while for Ivyp1 this range was
extended to 10 μM. The lysozyme concentration was kept constant at
70 nM in order to be able to compare our data with the previously
published results [13,15]. Although this enzyme concentration is too
high and therefore not optimal for the determination of Ki values for
slow tight inhibitors [45], this turbidimetric method did not allow for
signiﬁcantly lower enzyme concentrations.
Fig. 1 (Panel A) shows that the inhibition of HL by Ivyc is very strong
and the estimated apparent Ki value of 0.9 nM is comparable with the
inhibition of HEWL measured in our assays (Ki = 2.3 nM) and with
the Ki value of 1 nM reported previously for HEWL inhibition by Ivyc
(Fig. 1A inset). In contrast, Ivyp1 proved to be a less efﬁcient inhibitor
of HL than its E. coli counterpart (Fig. 1, Panel B) with an estimated ap-
parent Ki value of approximately 275 nM. Interestingly Ivyp1 inhibited
HEWL almost as strongly as Ivyc with a Ki value of 4.7 nM (Fig. 1B
inset). This value is only 2-fold higher than the 2.3 nM value estimated
from our HEWL–Ivyc inhibition data but is 5-fold lower than previously
reported [15] for the inhibition of HEWL by Ivyp1. It is doubtful that
these slight differences have arisen from using somewhat different
recombinant constructs for expression of Ivyc and Ivyp1 and they can
be more likely explained by small differences in the inhibition assay
A B
C D
S 
c(S
)
S 
c(S
)
S 
c(S
)
c(S
)
S 
Fig. 3. Sedimentation pattern of equimolar mixtures (solid line) of HEWL (top) and HL (bottom)with Ivyp1 (A, C) and Ivyc (B, D). Dashed lines correspond to the sedimentation patterns
obtained at a 1:2 inhibitor:enzyme molar ratio.
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weaker than that by Ivyc and it is a much more signiﬁcant difference
that can only be attributed to intrinsic differences in the interaction be-
tween these two lysozymes and the two inhibitors in this study.
The inhibitory loop shown to occlude the lysozyme active site is well
conserved amongmany Ivy homologs and it is thought to be a requisite
for lysozyme inhibition. However, a disulﬁde-linked cyclic synthetic
peptide carrying this amino acid sequence was not sufﬁcient to cause
inhibition of HL or HEWL activity in our inhibition assays even when
added in a large molar excess (data not shown).
3.2. State of association determined by analytical ultracentrifugation
The state of association of HEWL and HL was established through
equilibrium sedimentation AUC experiments. For both proteins the
Mr value calculated by a global ﬁt of the equilibrium curves is around
15 kDa, indicative of amonomeric state (Table 1). This result is in accor-
dancewith themonomer-dimer dissociation constant (5× 10−2M−1 atpH 6.8) given by Bruzzesi et al. for HLwhich indicates that the protein is
essentially monomeric up to millimolar concentrations [46].
In the same manner, the behavior of the inhibitors Ivyc and Ivyp1
was studied under the same conditions in sedimentation velocity AUC
experiments. The sedimentation pattern of Ivyc shows one major and
two minor peaks characterized by S20,w values around 2.80, 4.60, and
6.00 S (Table 1 and Fig. 2, Panel A) that can be attributed to dimers,
tetramers, and hexamers, respectively assuming a spherical shape of
the molecule. The percentage of each peak (75% dimers, 10% tetramers
and 15% hexamers) does not change noticeably over the concentration
range examined (13–160 μM) nor upon standing at 20 °C for 24 h.
Thus, Ivyc is largely dimeric, although these dimers can associate further
into tetramers and hexamers under the conditions tested.
The Ivyp1 sedimentation pattern likewise shows onemajor and two
minor peaks of S20,w values around 1.90, 4.50, and 7.20 S (Table 1 and
Fig. 2, Panel B). The main, slowest peak can be attributed to monomers
and the other two peaks to oligomers. Thus, in contrast to Ivyc, Ivyp1 is
largely monomeric (around 80%) even though the monomer tends to
A B
C D
Kd=2.1 nM Kd=19.3 nM 
Kd=291 nM Kd=1.5 nM 
Fig. 4. Isothermal titration calorimetry traces revealing the binding of HEWL (top) andHL (bottom) to Ivyp1 (A, C) and Ivyc (B, D). ITC titrationswere performed at room temperature and
consisted in 30 injections of 10 μL of each inhibitor (200 μM) into a 1.43mL sample cell containing solutions of HEWL or HL (20 μM). The titration curves were ﬁtted to a one-site binding
model using MicroCal Origin software. Average Kd values were determined from at least 3 replicas.
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bonds contribute to oligomer formation, the effect of 2 mM DTT on
the sedimentation behavior of Ivyp1 was analyzed (Fig. 2, Panel B
dashed line). In the presence of reducing agent, Ivyp1 sediments as a
single peak with the S20,w value of a monomer (approximately 1.8 S).
The addition of DTT to Ivyc likewise gave rise to the presence of only
one peak with S20,w = 2.35 S (Table 2 and Fig. 2, Panel A dashed line).
In principle, this sedimentation coefﬁcient, which is intermediate be-
tween those of monomers (1.8 S) and dimers (2.8 S), could be dueeither to a dissociating effect of DTT or to a signiﬁcant change in
shape. However, in the latter instance the frictional coefﬁcient should
change as well, which is not the case. The dissociation of Ivyc in the
presence of DTT was conﬁrmed in sedimentation equilibrium experi-
mentswhich yielded, at a concentration of 10 μM, aweight averagemo-
lecular mass, Mw, around 22 kDa, intermediate between those of
monomers and dimers.
Having characterized the behavior of the lysozymes and Ivy proteins
under study, their tendency to form complexes was analyzed. The
Fig. 5. (A) DSC data obtained for HEWL and its complexes with Ivyc and Ivyp1. (B) DSC
data obtained for HL and its complexes with Ivyc and Ivyp1.
3039Z. Liu et al. / Biochimica et Biophysica Acta 1848 (2015) 3032–3046interaction between Ivyp1 and HEWL was studied ﬁrst by sedimenta-
tion velocity at three different HEWL concentrations (10, 20 and
30 μM) while maintaining the concentration of Ivyp1 constant at
10 μM. At equimolar concentrations of HEWL and Ivyp1, the sedimenta-
tion pattern shows three peaks with S20,w values of 1.90, 2.9, and 4.5 STable 3
Thermal denaturation parameters for HEWL, HL, and their complexes with Ivyc and
Ivyp1 at pH 7.4.
Protein Tm (°C)a ΔHd (kcal/mol)c ΔHv (kcal/mol)d Re
HEWL 73.0 (72.8 ± 0.02)b 110.0 ± 0.5 124.6 ± 0.8 0.88
HL 70.5 (70.3 ± 0.02)b 94.4 ± 0.4 121.1 ± 0.7 0.77
Ivyc 65.8 (65.6 ± 0.02)b 87.9 ± 0.6 116.7 ± 0.9 0.75
Ivyp1f 58.3
(46.7 ± 0.5)b 3.8 ± 0.4 82.9 ± 11.6 0.04
(58.1 ± 0.02)b 57.9 ± 0.4 99.0 ± 6.7 0.59
HEWL/Ivyc 76.7 (76.3 ± 0.03)b 277.2 ± 4.1 225.4 ± 4.2 1.23
HEWL/Ivyp1 73.8 (74.0 ± 0.02)b 188.3 ± 1.7 222.0 ± 2.5 0.85
HL/Ivyc 75.4 (75.2 ± 0.03)b 219.8 ± 3.4 237.8 ± 4.72 0.92
HL/Ivyp1 71.1 (71.1 ± 0.03)b 212.6 ± 2.4 188.0 ± 2.70 1.13
a Tm is the transition midpoint temperature.
b Values of denaturation temperature before the parenthesis obtained by the peak
picking function of Origin 7.0; values in the parenthesis obtained by the “Non-2-State”
ﬁtting function.
c ΔHd is the calorimetric enthalpy of denaturation.
d ΔHv is the effective or van't Hoff denaturation enthalpy.
e R = ΔHd/ΔHv.
f Two denaturation temperatures were selected for the DSC curve ﬁtting.(Table 2, Fig. 3 Panel A). The relative percentage of the slowest peak in-
creases considerablywhenHEWL is inmolar excess (dashed line). Thus,
the slowest peak can be assigned to free HEWL and free Ivyp1 on the
basis of their sedimentation velocity. The 2.9 S peak corresponds to a
Mw value around 30 kDa and likely corresponds to a 1:1 complex
formed by a HEWL monomer bound to an Ivyp1 monomer. This peak
amounts to about 33% at equimolar concentration of Ivyp1 and HEWL
and becomes considerably less when the concentration of HEWL is
doubled. The 4.5 S peak amounts to less than 10%; it can be attributed
to Ivyp1 oligomers, possibly tetramers.
The interaction between Ivyc and HEWL was studied in a similar
fashion. Sedimentation velocity experiments at different HEWL and
constant Ivyc concentrations show three peaks with S20,w values of
1.8, 4.3, and 6.2–6.6 S (Table 2). The slowest peak can be assigned to
free HEWL, whereas the 4.2–4.3 S peak corresponds to an Mw value
around 54 kDa (based on the frictional coefﬁcient calculated by the
ﬁtting program) which is likely to correspond to a complex formed by
two HEWL monomers with one Ivyc dimer. Interestingly, this peak
becomes the main one at equimolar Ivyc and HEWL concentrations
(Fig. 3, Panel B). The broad peak around 6.2–6.6 S, which amounts to
about 5%, can be attributed to Ivyc oligomers and/or to a complex of
one Ivyc tetramer and four HEWL monomers.
The interaction of Ivyp1 and Ivyc with HL was characterized under
the same experimental conditions. The sedimentation velocity experi-
ments at equimolar Ivyc and HL concentrations display a single peak
of ~4.2 S (Table 2 and Fig. 3, Panel D) which corresponds to ~60 kDa,
based on the frictional coefﬁcient calculated by the ﬁtting program.
The sedimentation equilibrium experiments, performed at the same
1:1molar ratio and different total concentrations, conﬁrmed the forma-
tion of a 60 kDa species which can be assigned to a complex containing
one Ivyc dimer and two HLmonomers.WhenHL is inmolar excess over
Ivyc, a peak around 1.8 S appears in the sedimentation pattern as
expected for the HL monomer.
In the case of HL and Ivyp1, the sedimentation velocity proﬁle at
equimolar enzyme and inhibitor concentrations displays one peak
centered at 2.8 S (Table 2 and Fig. 3 Panel C) which can be assigned to
a 30 kDa species, representing the complex between one HL monomer
with one Ivyp1 monomer. Interestingly, when the concentration of HL
is increased at a constant Ivyp1 concentration (13 μM) the peak shifts
towards lower sedimentation coefﬁcients while no peak corresponding
to the free monomers appears, a behavior that may reﬂect the presence
of a fast association equilibrium. Taken together the ultracentrifugation
data show that in solution Ivyp1 complexes have a 1:1 stoichiometry,
while Ivyc have a 2:2 stoichiometry, similar to what was seen in the
crystal structures [15].3.3. Isothermal titration calorimetry experiments
The binding of Ivyc and Ivyp1 to HL and HEWLwas followed directly
by isothermal titration calorimetry (ITC) (Fig. 4). The dissociation con-
stants estimated for each of the complexes are in agreementwith the in-
hibition constants derived from the enzyme kinetics data presented
above. While Ivyc interacts with HL and HEWL with a similar afﬁnity
(Kd = 1.5 nM and Kd = 2.1 nM, respectively), Ivyp1 binds HEWL
much more strongly (Kd = 19.3 nM) than HL (Kd = 291 nM).
Interestingly, the binding of Ivyp1 toHLwas an endothermic process
while all other complexes were characterized by exothermic titration
curves. The thermodynamic parameters derived from these experi-
ments show that the interaction between Ivyp1 and HL proceeds with
unfavorable enthalpic values but is more entropically favorable than
the interactions between Ivyp1 and HEWL and the binding of Ivyc to
both HL and HEWLs, which are characterized by large enthalpic contri-
butions but rather small entropic changes. These results indicate that
the binding of Ivyp1 to HL differs fundamentally from its binding to
HEWL as well as from the Ivyc binding to both enzymes.
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Fig. 6.NMR experiments of Ivyp1.(A) 1H,15N HSQC NMR spectrum of the unbound state of Ivyp1 in aqueous solution. Residue peaks corresponding to themajor andminor conformations
are highlightedwith red circles (see text).(B) 1H,15N HSQCNMR spectrum of Ivyp1 bound toHL. The peaks experiencing large chemical shifts perturbations (compared to spectrumA) are
highlighted with red circles.(C)Weighted average secondary shifts (WASS) of the unbound (black bars) and the HL-bound states (white bar) of Ivyp1's.(D) Calculated chemical shift per-
turbations (CSPs) between the unbound and HL-bound states of Ivyp1.(E) Comparison of the {1H},15N NOE data for the unbound (white) and HL-bound state Ivyp1 (black). All secondary
structures along the sequence of Ivyp1 in both C and E ﬁgures are labeled at the bottomof each ﬁgure. The three loops that experience high CSPs are highlightedwith yellow shading. Note
that the loop between the ﬁnal two beta-strands is ﬂexible, as indicated by the smaller {1H}–15N NOE values.
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DSC experiments were used to determine the denaturation tem-
peratures of the individual proteins and their Ivy-lysozyme com-
plexes (Fig. 5 and Table 3). The dimeric Ivyc protein was more
stable than the monomeric Ivyp1 protein (65.8 °C versus 58.3 °C, re-
spectively). We also noted that HL denatures at a slightly lower tem-
perature than HEWL in agreement with previous studies (70.5 °C
versus 73 °C). The numbers obtained for the lysozymes are in agree-
ment with published values [47]. It is well known that binding of li-
gands to lysozyme increase its denaturation temperature [48].
Interestingly when we studied the 1:1 complexes of Ivyc with HL
and HEWL, we observed only one transition for these complexes at
increased denaturation temperatures of 75.4 °C and 76.7 °C, respec-
tively. This behavior is consistent with the high afﬁnity of these pro-
teins for each other. In the case of the Ivyp1 complexes, the complex
with HL and HEWL also gave rise to increased stability, although to a
lower extent. The HL denaturation temperature increased ~0.5 °C
upon binding Ivyp1, while the HEWL denaturation increased by
~0.8 °C. These trends are consistent with the data obtained by ITC.3.5. NMR characterization of Ivyp1 and its interaction with human
lysozyme
The lower molecular weight of the Ivyp1 complexes makes them
suitable for studies by high resolution solution-state NMR studies.
Using a series of HSQC-based triple resonance NMR spectroscopy ex-
periments, we could complete the backbone assignments for both
Ivyp1 in solution and for Ivyp1 in a complex with HL. Interestingly,
we did notice that several residues of Ivyp1 had dual 1H,15N HSQC
peaks and these are circled in the spectra (Fig. 6A). Most of these res-
idues are located between the last two beta-strands. Three proline
residues (P88, P91 and P98) are present in this region and conse-
quently, these dual peaks may be the result of the cis-trans confor-
mational exchange of their X-Pro bonds. Nonetheless, from the
weighted average secondary shift (WASS) analysis, it is clear that
in solution the protein has the same secondary structure as in the
available crystal structures (Fig. 6C). From the ITC experiments, we
know that the binding afﬁnity between Ivyp1 and HL is around 100
times weaker than the one between Ivyp1 and HEWL. Consistent
with this we found that the binding was in fast-exchange on the
Fig. 7. pH titrations and pKa determinations of the imidazole ring of Ivyp1 histidine sidechain. (A) 1Hε1 and 13Cε1 NMR chemical shifts plotted against the solution pH for the resonance of
H20 and H62 in Ivyp1. (B) 1Hε1 and 13Cε1 NMR chemical shifts plotted against the solution pH for H62 in the Ivyp1/HL complex. (C) The best ﬁts for the pH titration curves and the de-
termination of the pKa values.
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observed that many of the spectral peaks shifted when nonlabeled
HL is titrated into the sample. However, several regions of the pro-
tein showed much larger CSPs than the remaining parts of Ivyp1
and several representative peaks are highlighted in Fig. 6B. Not sur-
prisingly, the highly conserved inhibition loop (-CKPHDC-) is one
of these regions. In fact, the 1H,15N backbone amide resonance of
His62 in the inhibition loop could not be identiﬁed in Fig. 6A, due
to extensive exchange broadening. However, other residues in this
loop experienced large chemical shift changes and conﬁrmed that
in solution this loop is directly involved as part of the binding inter-
face with HL. In addition to the inhibition loop, we also found two
other loop regions that seem to be involved in the binding. One
loop (P1) is located between the N-terminal end of helix α3 and
the ﬁrst beta strand β1 while the second loop (P2) is located
between the ﬁnal two beta-strands (β4 and β5). As shown by
proton-detected 15N NMR relaxation measurements, both these
loops are more ﬂexible than the other parts of the Ivyp1 protein in
aqueous solution (Fig. 6E). Nonetheless in the Ivyp1-HL protein–pro-
tein complex, these two loops become much more rigid; these
changes in the backbone dynamics are therefore consistent with
the NMR CSP data (Fig. 6D). The C-terminal Trp128 residue also ex-
perienced a large CSP (N1.0 ppm), which strongly suggests that the
C-terminal tail of Ivyp1 is also important for the interaction with
HL. Interestingly, we did notice that both the backbone amide and
sidechain indole HN resonances of Trp128 have two peaks in the
HSQC spectra of Ivyp1 (Fig. 6A). The proximal proline residue
(Pro126) close to Trp128 may be responsible for these dual peaks,
like those seen for loop P2. Smaller CSPs were also observed for the
N-terminal residues of the protein. When mapped onto the Ivyp1
protein surface, all the perturbed regions are located on one side of
the Ivyp1 structure, which forms a highly negatively charged binding
interface. This makes a suitable binding surface for the cationic lyso-
zyme proteins.3.6. Determination of the protonation state of His62 of Ivyp1
As mentioned above, we found that the amide proton of His62 was
too broad to be detected in the 1H,15N HSQC NMR spectra of Ivyp1 in
aqueous solution. However, once Ivyp1 was saturated by HL, the peak
for the His62 amide group could be clearly observed (Fig. 6B). These
changes indicate that the inhibition loop may adopt multiple exchang-
ing conformations in the absence of HL or HEWL binding. In order to de-
termine the protonation state of the sidechain imidazole ring of His62 in
Ivyp1 in the free and bound states, we collected a series of 2D 1H,13C
HSQC spectra of Ivyp1 alone or saturated with HL at different pH values
(Figs. 7A, B). The chemical shifts for the 1Hε1 and 13Cε1 resonance of
His62 andHis20 of eachHSQC spectrawere recorded and thepKa values
were determined by ﬁtting these titration data (Fig. 7C). There are two
His residues in wild type Ivyp1, and in order to be certain about the
sidechain peak assignments, we made a site-directed mutation
(H20A) in Ivyp1. For Ivyp1 in aqueous solution, the peaks from both
His20 and His62 can be traced from low to high pH. We determined
pKa values of both residues by ﬁtting the titration curves. His62 has a
slightly higher pKa value (6.35 ± 0.08) than His20 (5.75 ± 0.05).
These pKa values are close to those measured for exposed His residues
[49]. In the complex with HL, His62 of Ivyp1 experiences only small
chemical shift changes during a pH titration experiment followed by
1H,13C HSQC spectra. This is consistent with the notion that the
sidechain becomes “buried” in the active site of HL. Moreover, the
peak also becomes broader when the pH is increasing, and the
resonance of His62 can no longer be detected above pH 8.5. From this
pattern we can estimate that the pKa value of His62 in the complex is
higher than 8.5 [50]. From the X-ray structures solved previously, it is
known that several water molecules are involved in the binding inter-
face between Ivyc/Ivyp1 and HEWL (Figs. 8A and C). The peak broaden-
ing observed can be the result of exchange among the sidechain protons
of His62, the bound water molecules and free water molecules in the
surrounding solution.
Fig. 8.Modeling and comparisons of Ivy proteins and their complexeswith lysozymes. (A) Structure of the Ivyc/HEWL complex. The dimer of Ivyc is shown in a cartoon representation and
the electronic potential surfaces of the two HEWL subunits were calculated. The highly negatively charged catalytic crevice of each lysozyme subunit is occupied by the His residue of the
Ivy inhibition loop (-CKPHDC-). Watermolecules involved in this process are shown aswhite beads. The Ivyp1 structure in the Ivyp1/HEWL complex was overlapped with one subunit of
the Ivyc dimer for comparison. All secondary structure elements were highlighted on the alternative subunit of the Ivyc dimer. (B) Cartoon representation of both the Ivyc dimer (silver)
and the Ivyp1monomer (green). Several Phe residues (F112, F126 and F128) on the Ivyc dimer interface are shown in a stick representation. (C) Cartoon representation of the Ivyp1/HEWL
complex (white). With the structure of HL (green) overlapped onto the HEWL structure. The inhibition loop and the charged residues in the binding interface are labeled. The residues
from Ivyp1 are labeled without frames, labels with yellow frames represent residues from HEWL, while labels with black frames indicate residues from HL. Water molecules involved
in the inhibition were shown as red balls. Possible salt bridges are indicted with dashed yellow lines. Other residues involved in the binding interface were shown in light-blue on the
ribbon structure.
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Since its initial discovery as a human innate immunity host-defense
protein by Sir Alexander Fleming in 1922 [51], lysozyme has been the
focus of signiﬁcant research. It was also the ﬁrst enzyme to have its
structure determined by X-ray crystallography and has become a
model in the study of protein structure and folding [5,52,53]. The recent
discovery of bacterial periplasmic Ivy proteins capable of inhibiting the
lysozyme activity has opened yet another ﬁeld of research aimed at
establishing their putative role in bacterial resistance and survival in
lysozyme rich ﬂuids [7,28].
The lysozyme active site becomes occluded by a highly conserved
loop that protrudes from the Ivymolecules and forms speciﬁc hydrogen
bonding interactions with the catalytically important Glu35 and Asp52
sidechains in the lysozyme active site [15]. The high conservation in
many Ivy proteins of the sequence ﬂanking histidine (-CKPHDC-) and
the behavior of site-speciﬁc Ivyc His60 variants [15] point to thefunctional relevance of this loop. However, when a disulﬁde-linked cy-
clic CKPHDC peptidewas synthesized and its lysozyme inhibitory activ-
ity was tested, no inhibition was observed in our turbidimetric assay
even when the peptide was added in large molar excess (not shown).
These results suggest that although the presence of this loop is required
for inhibition, other structural elements are essential for placing the in-
hibitory loop in its effective position. In fact, the structure of the Ivyc and
Ivyp1 complexeswithHEWL revealed that rather large surface areas are
involved in the interaction between the HEWL and the Ivy inhibitors.
The surface area buried in the dimeric Ivyc–HEWL complex
(~1340 Å2) is larger than for the monomeric Ivyp1 complex with
HEWL (~1000 Å2) [15].
Since Ivy inhibitors are produced by a group of Gram-negative
bacteria including several human pathogens, we were particularly in-
terested in their interaction with HL. Our enzyme inhibition assays
showed large differences in the inhibitory strength of Ivyc and Ivyp1
on HL. Ivyp1 was a less effective inhibitor of HL (Ki = 275 nM) than
Fig. 9. Electrostatic surface and cartoon representations of Ivyc/HEWL (A), Ivyc and Ivyp1 in complexwithHEWL (B, D, E) orHL (C) [15]. The electrostatic plotswere generatedwith Pymol
(the PyMOL Molecular Graphics System, DeLano, W.L., http://www.pymol.org). Electrostatic surfaces for the dimer Ivyc (A) and monomer Ivyp1 (D) were displayed. A continuous posi-
tively charged surface on one side of Ivyc and continues negatively charged surface at the C-terminus of Ivyp1 are clearly present (green square). The dotted line encloses an acidic area in
HL (C) that is positively charged in HEWL (B). This area is directly exposed to the Ivy inhibitors in the complexeswith HEWL (represented as cartoon in B, C) and it faces a large negatively
charged loop in the Ivyp1monomer (C) in contrast to the shorter andmore positively charged loop that is present in the Ivyc dimer (B). The backbone of Ivyp1/HEWL complexwas colored
with B-factors along the sequence with red and yellow having the highest B-factors (E). Residues of the long loop of Ivyp1 have high B-factors, which is consistent with our {1H},15N NOE
data.
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sus HEWL (Ki = 2.3 nM and 4.7 nM, respectively). In order to explore
these differences further, we studied the interaction of these two Ivy in-
hibitors with both HL and HEWLs by ITC. The ITC data conﬁrmed that
Ivyp1 indeed binds to HL in a weaker manner (Kd = 291 nM) than to
HEWL (Kd = 19.3 nM). We also established that Ivyc binds to HL and
HEWLs with similar afﬁnities (Kd = 1.5 nM and Kd = 2.1 nM,
respectively).
While DSC is frequently used to determine how the binding of small
ligands increases the denaturation temperature of proteins and DNAs
[54,55], this technique has only seen limited use to study the stability
of protein–protein complexes. In some instances complexes of a folded
and a natively unfolded protein have been studied, where the latter
does not show melting behaviors [56]. Nonetheless, studies of proteo-
lytic enzymes such as trypsin and chymotrypsin,with their cognate pro-
teinase inhibitors [57–59], as well as ribonucleases, such as barnase,
together with their barstar protein inhibitors [60,61], have all shown
increased stability for the two proteins in the complex, in agreement
with the theory originally proposed by Brandts and Lin [62]. Clearly,
the complexes of HEWL and HL with Ivyp1 and Ivyc behave in a similar
manner. It is noteworthy that the Ivyp1/HL complexes experienced the
lowest increase in the denaturation temperature in agreement with its
weaker binding.
Our sedimentation velocity and equilibrium data revealed that the
differences in binding afﬁnity measured by ITC and enzyme inhibition
assays are not due to a different stoichiometry of the Ivy complexeswith HL. In fact these experiments corroborated the notion that dimeric
Ivyc binds two monomers of HL to form a tetramer of approximately
60 kDa and Ivyp1 interacts with one HL monomer to form a heterodi-
mer of approximately 30 kDa (Table 2).
For a deeper understanding of the differences between Ivyc and
Ivyp1 and their interactionwith lysozymes, we reexamined the electro-
static surfaces and structures of both proteins. The dimeric state of Ivyc
is mostlymaintained by interactions along the C-terminal β6 strand and
it also involves the last two helices of the two subunits. Several impor-
tant hydrophobic residues (Ile105, Phe112, Phe126 and Phe128) on
this interface are prominent in Ivyc (Fig. 8B), but are missing in Ivyp1.
By aligning the dimer Ivyc and monomer Ivyp1, it can be readily seen
that the last helix of Ivyc is missing in Ivyp1. The dimer form of Ivyc
may be important for its tight binding with c-type lysozymes. From a
detailed analysis of the electronic potential surface of the Ivyc/HEWL
complex, we identiﬁed several important salt bridges between the
Ivyc dimer and HEWL, including Glu87/Asp61 of Ivyc and Arg114 of
HEWL (Fig. 8A), as well as a salt bridge between Arg5 of HEWL and
Asp101 of the second Ivyc subunit. Moreover, the ﬁnal beta-strand
(β6) is part of thedimer interface in Ivyc and it is possible that dimer for-
mation helps Ivyc avoid electrostatic repulsions when facing the
negative patch in HL. The residues involved in dimer formation are
not conserved in Ivyp1, which as a result is monomeric and exposes a
large negatively charged area to the lysozyme binding interface.
Also, a closer examination of the HL electrostatic surface plots
revealed important differences with respect to HEWL in the residues
3045Z. Liu et al. / Biochimica et Biophysica Acta 1848 (2015) 3032–3046located at the interface of the HEWL–Ivy complexes. The substitution of
Gly4 and Ser86 in HEWL by Glu4 and Asp87 in HL results in the forma-
tion of a relatively negative patch on the surface of HL in a region that is
largely positive in HEWL (Figs. 9B and C).We propose that this negative
patch affects the HL binding to Ivyp1 because it faces the P2 loop that is
not only larger in Ivyp1 (14 residues) than in Ivyc (6 residues) but it is
also very negatively charged due to the presence of four negative resi-
dues Asp89, Glu90, Glu93, and Asp125 (Figs. S1 and 9D). The corre-
sponding loop in Ivyc is much less negatively charged. As mentioned
before, our NMR dynamics data show that this loop is quite ﬂexible
when the target protein is not bound. The higher B-factors seen for
this loop in the crystal structure of Ivyp1/HEWL complex are also in
agreement with our results (see Fig. 9E). It should be noted that the
DSC results obtained for Ivyp1 reveal that a small portion of the protein
denatures at a lower temperature (46.7 °C) than the main part of the
protein (58.1 °C) (see Supplementary Fig. S2). It is tempting to speculate
that this represents the ﬂexible region of this protein.
In the meantime, the discovery that some mutated forms of human
lysozyme can form amyloid ﬁbrils [53,63–66] has given way to new in-
vestigations looking for potential ligands that abrogate ﬁbrils formation
leading to human disease by stabilizing the structure of lysozyme
amyloidogenic variants. One successful trial has already been reported
of a camelid antibody fragment raised against wild type human lyso-
zyme that was able to inhibit the in-vitro aggregation of the human
lysozyme variant D67H [67–69]. Also a chaperone protein has been
used to prevent lysozyme amyloid formation [70]. We speculate that
Ivy inhibitors could represent potential candidates for this restorative
approach since particularly Ivyc binds HL with high afﬁnity and forms
very stable complexes. To that effect, the data presented here on the in-
teraction between two lysozyme-Ivy complexes provides useful infor-
mation on the factors that determine the afﬁnity between the two
partners, a key factor in the bacterial defense strategy from the lytic ef-
fect of lysozyme and, aswell, it is critical knowledge for the potential fu-
ture therapeutic use of these inhibitors.
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